

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	1Q `08	1Q `07
MERCK / SCHERING-PLOUGH	\$ 392.8	\$ 347.2
ASTRAZENECA LP	131.1	211.9
Other ⁽¹⁾	128.2	93.5
TOTAL	\$ 652.1	\$ 652.6

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & Johnson[®]Merck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	1Q `08	1Q `07
FRONTLINE, other fipronil	\$ 341.6	\$ 327.6
BIOLOGICALS	174.4	153.3
IVOMEK, HEARTGARD, other avermectins	146.1	137.4
Other Animal Health	71.5	59.4
TOTAL MERIAL SALES	\$ 733.6	\$ 677.7

Sanofi Pasteur-MSD	1Q `08	1Q `07
GARDASIL	\$ 239.8	\$ 30.2
VIRAL VACCINES	22.7	20.1
HEPATITIS VACCINES	18.0	16.7
Other Vaccines	130.9	127.8
TOTAL SANOFI PASTEUR-MSD SALES	\$ 411.4	\$ 194.8

Merck / Schering-Plough Collaboration	1Q `08	1Q `07
VYTORIN	\$ 651.2	\$ 623.8
ZETIA	581.7	544.0
TOTAL MERCK / SCHERING-PLOUGH SALES	\$ 1,232.9	\$ 1,167.8

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	1Q `08	1Q `07
INTEREST INCOME	\$ (169.5)	\$ (181.7)
INTEREST EXPENSE	72.6	102.4
EXCHANGE LOSSES (GAINS)	12.6	(19.6)
MINORITY INTERESTS	31.9	30.6
Other, net ⁽¹⁾	(2,124.9)	(187.7)
TOTAL	\$ (2,177.3)	\$ (256.0)

⁽¹⁾ Other, net in the first quarter of 2008 primarily reflects a gain of \$2.2 billion related to a distribution from AstraZeneca LP.

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2008

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	1Q '08 vs. 1Q '07					
	TOTAL	TOTAL	U.S.	U.S.	Foreign	Foreign
	% CHG	\$	% CHG	\$	% CHG	\$
COZAAR / HYZAAR	6%	847	-2%	299	11%	548
FOSAMAX	-37%	470	-58%	202	3%	268
SINGULAIR	10%	1,104	1%	714	33%	389
Vaccines:						
GARDASIL	7%	390	-6%	293	82%	97
ROTATEQ	*	190	*	179	*	11
ZOSTAVAX	72%	74	72%	73	N/A	-
OTHER VIRAL VACCINES ⁽¹⁾	-8%	226	-11%	202	25%	24
HEPATITIS VACCINES	-53%	34	-59%	25	-21%	9
OTHER VACCINES	-21%	73	-55%	29	65%	43
Other Reported Products:						
ARCOXIA	16%	93	N/A	-	16%	93
CANCIDAS	11%	149	-22%	30	24%	119
COSOPT / TRUSOPT	8%	201	-3%	81	17%	121
CRIXIVAN / STOCRIN	-9%	75	-36%	4	-6%	72
EMEND	25%	60	12%	40	66%	19
INVANZ	33%	55	25%	28	43%	27
ISENTRESS	*	47	*	30	*	17
JANUVIA	*	272	*	228	*	44
JANUMET	*	58	*	55	*	4
MAXALT	13%	122	11%	79	17%	43
PRIMAXIN	3%	203	-16%	51	11%	152
PROPECIA	10%	105	1%	37	16%	68
PROSCAR	-32%	85	-88%	3	-17%	82
TIMOPTIC / TIMOPTIC XE	1%	29	-13%	2	2%	27
VASOTEC / VASERETIC	-21%	96	N/A	-	-21%	96
ZOCOR	-31%	179	-60%	28	-20%	151
ZOLINZA	72%	4	61%	4	N/A	-

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	1Q '08	% CHG	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	\$ 5,822	1%	-2	-2	4
U.S. (\$ MM)	3,296	-6%	-6	--	N/A
Foreign (\$ MM)	2,526	12%	5	-4	11